Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biochem Pharmacol ; 83(12): 1634-42, 2012 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-22445931

RESUMO

Although the vast majority of patients with acute lymphocytic leukemia (ALL) attain remission with modern therapies, relapsed leukemia will continue to be a common malignancy both in childhood and in adults, until new treatments are available. Therapeutic options for advanced B-cell acute lymphocytic leukemia are still limited and acquired drug resistance and extramedullary tissue infiltration are two major obstacles during treatment. The prenylflavonoid xanthohumol (XN) has shown in vitro and in vivo therapeutic potential against a range of tumors. In the present study we investigated the effects of XN on B-ALL cells in vitro and in an ALL-like xenograft mouse model. Treatment of ALL cell lines with XN resulted in growth arrest and apoptosis induction. XN retained its cytotoxicity when adriamycin resistant cells were examined while ALL cell clones adapted to long-term exposure to XN resulted highly responsive to cytotoxic drugs. Administration of 50µg XN/mouse (5 days/week) significantly increased animal life span by delaying the insurgence of neurological disorders due to leukemic cells dissemination. In agreement with a less invasive phenotype, cell migration and invasion were impaired by XN and basal levels of FAK, AKT and NF-κB signaling pathways were down-regulated in ALL cells upon XN exposure. Our data indicate that XN has significant antileukemic activity both in vitro and in vivo, which associates with impaired cell migration and invasion. Interestingly, this activity overcomes mechanisms leading to drug-resistance. XN represents a promising agent perspective for ALL therapy and recurrence prevention and would deserve clinical testing in the near future.


Assuntos
Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Flavonoides/farmacologia , Infiltração Leucêmica/patologia , NF-kappa B/antagonistas & inibidores , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Propiofenonas/farmacologia , Proteínas Proto-Oncogênicas c-akt/antagonistas & inibidores , Animais , Linhagem Celular Tumoral , Humanos , Camundongos , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
2.
Int J Cancer ; 131(3): 582-90, 2012 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-22015967

RESUMO

Current diagnostic tools cannot predict clinical failure and androgen-independent disease progression for patients with prostate cancer (PC). The survival signaling pathways of prostate cells play a central role in the progression of tumors to a neuroendocrine (NE) phenotype. NE cells demonstrate attributes that suggest that they are an integral part of the signaling cascade leading to castration-resistant PC. In this study, making use of in vitro neuroendocrine differentiation (NED) of human LNCaP and mouse TRAMP-C2 cells after androgen withdrawal, and of the transgenic adenocarcinoma of mouse prostate (TRAMP) model, we characterized a sequence of molecular events leading to NED and identified a number of markers that could be detectable by routine analyses not only in castration resistant PC but also in hormone naïve PC at the time of initial diagnosis. We found that NED associates with AKT activation that in turn regulates heterogeneous nuclear ribonucleoprotein K (hnRNP K), androgen receptor (AR) and ß-catenin levels. Addition of molecules targeting membrane-bound receptors and protein kinases blocks NE differentiation in LNCaP and TRAMP-C2 cells. The extent of AKT phosphorylation and hnRNP K, AR and ß-catenin levels may have a potential value as prognostic indicators discriminating between androgen-responsive and unresponsive cells and could be used as molecular targets to monitor the anti-tumor action of new therapeutic protocols based on antireceptor agents and/or neuroendocrine hormone antagonists.


Assuntos
Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Células Neuroendócrinas/metabolismo , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia , Transdução de Sinais , Androgênios/metabolismo , Animais , Diferenciação Celular , Linhagem Celular Tumoral , Ribonucleoproteínas Nucleares Heterogêneas Grupo K/metabolismo , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Células Neuroendócrinas/patologia , Fosforilação , Proteínas Proto-Oncogênicas c-akt/metabolismo , Receptores Androgênicos/metabolismo , beta Catenina/metabolismo
3.
Recent Pat Anticancer Drug Discov ; 4(3): 207-15, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19715554

RESUMO

Non-invasive in vivo imaging offers great potential to facilitate translational drug development research at the animal testing phase. The emerging luminescent nanoparticles or quantum dots provide a new type of biological agents that can improve these applications. The advantages of luminescent nanoparticles for biological applications include their high quantum yield, color availability, good photo-stability, large surface-to-volume ratio, surface functionality, and small size. These properties could improve the sensitivity of biological detection and imaging by at least 10- to 100-fold and make them an exceptional tool for live-cell imaging. In this review patents on applications of semiconductor quantum dots for in vivo imaging are discussed.


Assuntos
Imagem Molecular/métodos , Neoplasias/diagnóstico , Pontos Quânticos , Animais , Fluorometria/métodos , Humanos , Semicondutores , Ensaios Antitumorais Modelo de Xenoenxerto/métodos
4.
Eur J Cancer ; 44(15): 2296-311, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18722110

RESUMO

Human malignant pleural mesothelioma (MPM) is a dreadful disease and there is still no standard therapy available for a consistent therapeutic approach. This research is aimed at the evaluation of the potential therapeutic effect of a specific nicotinic receptor (nAChR) antagonist, namely alpha-Cobratoxin (alpha-CbT). Its effectiveness was tested in mesothelioma cell lines and in primary mesothelioma cells in vitro, as well as in vivo, in orthotopically xenotransplanted NOD/SCID mice. Cells showed alpha7-nAChR expression and their growth was significantly inhibited by alpha-CbT. Severe induction of apoptosis was observed after exposure to alpha-CbT [IC(80-90)]. Apoptosis was characterised by: change in mitochondrial potential, caspase-3 cleavage, down-regulation of mRNA and protein for survivin, XIAP, IAP1, IAP2 and Bcl-XL, inhibition by caspase-3 inhibitor. In vivo, the alpha-CbT acute LD(50) was 0.15 mg/kg. The LD(100) [0.24 mg/kg] induced fatal respiratory failure and massive kidney necrosis. Phase II experiments with 0.12 ng/kg alpha-CbT (1/1000 of LD(10)) were done in 53 xenotransplanted mice, inhibiting tumour development as confirmed by chest X-ray examinations, autopsy and microscopical findings. The growth of human proliferating T lymphocytes and of mesothelial cells in primary culture was not affected by alpha-CbT. Non-immunogenic derivatives of the alpha-CbT molecule need to be developed for possible human use.


Assuntos
Antineoplásicos/uso terapêutico , Proteínas Neurotóxicas de Elapídeos/uso terapêutico , Mesotelioma/tratamento farmacológico , Antagonistas Nicotínicos/uso terapêutico , Neoplasias Pleurais/tratamento farmacológico , Receptores Nicotínicos/metabolismo , Animais , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Proteínas Neurotóxicas de Elapídeos/farmacologia , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Humanos , Mesotelioma/metabolismo , Mesotelioma/patologia , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Proteínas de Neoplasias/metabolismo , Transplante de Neoplasias , Antagonistas Nicotínicos/farmacologia , Neoplasias Pleurais/metabolismo , Neoplasias Pleurais/patologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Transplante Heterólogo , Células Tumorais Cultivadas , Receptor Nicotínico de Acetilcolina alfa7
5.
Peptides ; 28(9): 1738-45, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17524522

RESUMO

The distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP receptors in the brain of amphibians has been previously described. In the present study, we have investigated the ontogeny of the selective PACAP receptor, PAC1-R, and the PACAP-vasoactive intestinal polypeptide (VIP) mutual receptor, VPAC1-R, in frog embryos by whole-mount in situ hybridization histochemistry. At stage 20, expression of PAC1-R and/or VPAC1-R mRNAs was detected in the brain, the auditory vesicles, the external gills, the buds of the lateral lines and the coelomatic cavity. At stage 25, PAC1-R and/or VPAC1-R mRNAs were observed in the buds of the orbital lateral line, the pancreas and heart. At stage 30, PAC1-R and VPAC1-R mRNAs were widely distributed in the telencephalon and diencephalon as well as in the bud of the lateral line, the heart and the pancreas. The anatomical distribution of PAC1-R and VPAC1-R mRNAs, although similar, did not totally overlap, indicating that PACAP and VIP may exert differential effects in frog during development.


Assuntos
Embrião não Mamífero/metabolismo , Rana esculenta/genética , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/genética , Receptores Tipo I de Polipeptídeo Intestinal Vasoativo/genética , Animais , Encéfalo/embriologia , Encéfalo/metabolismo , Embrião não Mamífero/embriologia , Regulação da Expressão Gênica no Desenvolvimento , Hibridização In Situ , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Rana esculenta/embriologia
6.
Ann N Y Acad Sci ; 1070: 201-4, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16888166

RESUMO

This study describes the expression of PAC1 and VPAC1 receptor (PAC1-R and VPAC1-R) mRNAs in the brain of frog (Rana esculenta) during development. PAC1-R mRNA was detected in the periventricular and subependymal layers of the thalamus and epithalamus and in the ependymal layer of the mesencephalon and rhombencephalon (stage 20), in the amygdala, in the habenular complex, in the periventricular nucleus of the hypothalamus, and in the ventral cerebellum (stage 30). VPAC1-R mRNA expression was observed only at stage 20, in the floor of the hypothalamus. These results suggest that, in amphibians, pituitary adenylate cyclase-activating polypeptide (PACAP) may play a role in brain development.


Assuntos
Encéfalo/crescimento & desenvolvimento , Encéfalo/metabolismo , Regulação da Expressão Gênica no Desenvolvimento , Ranidae/crescimento & desenvolvimento , Ranidae/genética , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase/genética , Receptores Tipo I de Polipeptídeo Intestinal Vasoativo/genética , Animais
7.
J Comp Neurol ; 497(5): 717-33, 2006 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-16786560

RESUMO

Two forms of somatostatin are expressed in the frog brain, i.e., somatostatin-14 (SS1) and the [Pro(2), Met(13)]somatostatin-14 variant (SS2). We have previously described the ontogeny of SS1-immunoreactive cells in the brain of Rana esculenta. In the present study, we have investigated the distribution of prepro-SS2 (PSS2)-expressing neurons in the brain of the same species during development by using antibodies directed against the N-flanking region of SS2 (PSS2(54-66)). Immunoreactive perikarya first appeared in the ventral hypothalamus at stages IV-VII. Subsequently, positive neurons were seen in the nucleus of the diagonal band of Broca, the anterior preoptic area, the posterior tuberculum (stages VIII-XII), as well as the dorsal (stages XIII-XV) and medial (stages XIX-XX) periventricular preoptic nucleus. At metamorphic climax and in newly metamorphosed frogs, positive perikarya were found in the striatum and in the interpeduncular nucleus. PSS2(54-66)-immunoreactive fibers were already widely distributed during the first stages of development, indicating that SS2 may act as a neuromodulator and/or neurotransmitter during ontogeny. The presence of PSS2(54-66)-positive nerve fibers in olfactory structures suggests that, in tadpoles, SS2 may be involved in the processing of olfactory information. The occurrence of PSS2(54-66)-like immunoreactivity in taste buds, and in the olfactory and vomeronasal organs indicates that SS2 may mediate the unconditioned and reinforcing properties of natural chemicals. Finally, the intenseexpression of PSS2(54-66)-like immunoreactivity in melanotrope cells of the pituitary suggests that SS2 may diffuse toward the pars distalis to regulate the activity of adenohypophysial cells during tadpole development.


Assuntos
Encéfalo/metabolismo , Hipófise/metabolismo , Rana esculenta/metabolismo , Órgãos dos Sentidos/metabolismo , Somatostatina/metabolismo , Animais , Encéfalo/crescimento & desenvolvimento , Imuno-Histoquímica , Larva/crescimento & desenvolvimento , Larva/metabolismo , Metamorfose Biológica/fisiologia , Hipófise/crescimento & desenvolvimento , Rana esculenta/anatomia & histologia , Rana esculenta/crescimento & desenvolvimento , Órgãos dos Sentidos/crescimento & desenvolvimento , Somatostatina/análogos & derivados
8.
Brain Res Dev Brain Res ; 151(1-2): 169-85, 2004 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-15246703

RESUMO

The distribution of Pituitary adenylate cyclase-activating polypeptide (PACAP) was investigated in the brain, pituitary and sensory organs of the zebrafish, Danio rerio, during development, in juvenile and adult specimens, using the immunofluorescence method. In 24 h post fertilization (hpf) embryos, PACAP immunoreactive cells appeared in the rostral telencephalon, dorsal diencephalon, caudal and medial rhombencephalon, spinal cord and retina. At 48 hpf stage, positive cells were present in the dorsal diencephalon, medial rhombencephalon, spinal cord, retina and olfactory placode (Op). At 72 hpf stage, additional immunoreactive elements appeared in the medial telencephalon, hypothalamus, mesencephalic tegmentum, retina and otic sensory epithelium (Ose). At day 5, new immunoreactive cells were found in the anterior rhombencephalon and pituitary pars distalis. At day 13, positive cells were mainly concentrated in the mesencephalic tegmentum and spinal cord. In the telencephalon, diencephalon, rhombencephalon and pituitary, the distribution of positive cells was similar to that previously reported. At 1 month stage, positive cells were detected in the hypothalamus, nucleus of the medial longitudinal fascicle (nMlf), rhombencephalic griseum centrale (Gc) and pituitary pars distalis. At 2-3 month stages, immunoreactive elements were found in several hypothalamic nuclei, in the mesencephalic nucleus isthmi, cerebellum and pituitary. In adults, PACAP immunoreactivity was confined to a few brain regions and the pituitary. PACAP immunoreactivity was transiently expressed in several regions suggesting that the peptide may have a role in the control of cells differentiation and proliferation during zebrafish ontogeny. The finding of positive fibers in the pituitary from day 5 onward indicates that PACAP may function from this stage as a hypophysiotropic peptide.


Assuntos
Encéfalo/metabolismo , Neuropeptídeos/metabolismo , Órgãos dos Sentidos/metabolismo , Medula Espinal/metabolismo , Fatores Etários , Animais , Encéfalo/crescimento & desenvolvimento , Embrião não Mamífero/metabolismo , Imunofluorescência/métodos , Larva/metabolismo , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Receptores de Peptídeo Intestinal Vasoativo , Órgãos dos Sentidos/crescimento & desenvolvimento , Medula Espinal/crescimento & desenvolvimento , Peixe-Zebra , Proteínas de Peixe-Zebra
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...